Literature DB >> 12939582

Epidemiology of primary hepatic malignancies in U.S. children.

Anil Darbari1, Keith M Sabin, Craig N Shapiro, Kathleen B Schwarz.   

Abstract

The epidemiology of primary hepatic malignancies in U.S. children is poorly characterized. We analyzed the incidence, mortality, and characteristics of primary hepatic malignancies in U.S. residents less than 20 years of age. Fatal primary hepatic malignancies in persons less than 20 years of age, between 1979 and 1996, were identified using the multiple-cause-of-death database (National Center for Health Statistics). Histologically confirmed primary hepatic malignancies occurring between 1973 and 1997 were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Between 1979 and 1996, 918 primary hepatic malignancy deaths (average, 0.7/1,000,000/year) were reported nationally among persons less than 20 years of age; rates were higher among Asians and among foreign-born children. Between 1973 and 1997, 271 primary hepatic malignancy cases were reported to SEER among persons less than 20 years of age, of which 184 (67%) and 83 (31%) were hepatoblastoma and hepatocellular carcinoma, respectively. Among children less than 5 years of age, hepatoblastoma accounted for 91% of primary hepatic malignancy cases, whereas among those 15 to 19 years of age, hepatocellular carcinoma accounted for 87% of cases. Five-year survival for hepatoblastoma was 52%, compared with 18% for hepatocellular carcinoma. In the SEER sites, between 1973 and 1977 and 1993 and 1997, hepatoblastoma rates increased (0.6 to 1.2/1,000,000, respectively), while hepatocellular carcinoma rates decreased (0.45 to 0.29/1,000,000, respectively). In conclusion, histologically confirmed hepatocellular carcinoma was reported in children less than 5 years of age, also, where hepatoblastoma is the predominant primary hepatic malignancy. Hepatocellular carcinoma has worse survival rates than hepatoblastoma, and its incidence has not increased. Better maintenance of databases may provide information about associated factors behind this unexpected occurrence.

Entities:  

Mesh:

Year:  2003        PMID: 12939582     DOI: 10.1053/jhep.2003.50375

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  63 in total

Review 1.  Neonatal tumours.

Authors:  Kokila Lakhoo; Helen Sowerbutts
Journal:  Pediatr Surg Int       Date:  2010-10-19       Impact factor: 1.827

2.  Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

3.  Hepatoblastoma: why so many low-birth-weight infants?

Authors:  Thomas L Slovis; Derek J Roebuck
Journal:  Pediatr Radiol       Date:  2006-03

Review 4.  Risk factors for hepatocellular carcinoma.

Authors:  D Alan Herbst; K Rajender Reddy
Journal:  Clin Liver Dis (Hoboken)       Date:  2013-01-23

5.  What do we know about the etiology of hepatoblastoma?

Authors:  Lucie M Turcotte; Logan G Spector
Journal:  Hepat Oncol       Date:  2013-12-20

Review 6.  Primary malignant liver tumors in children.

Authors:  Sandeep Agarwala
Journal:  Indian J Pediatr       Date:  2012-03-01       Impact factor: 1.967

7.  The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.

Authors:  Laura L Stafman; Mary G Waldrop; Adele P Williams; Jamie M Aye; Jerry E Stewart; Elizabeth Mroczek-Musulman; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle
Journal:  J Pediatr Surg       Date:  2019-02-28       Impact factor: 2.545

Review 8.  Liver transplantation for malignancies.

Authors:  Bijan Eghtesad; Federico Aucejo
Journal:  J Gastrointest Cancer       Date:  2014-09

9.  The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model.

Authors:  Piotr Czauderna; Beate Haeberle; Eiso Hiyama; Arun Rangaswami; Mark Krailo; Rudolf Maibach; Eugenia Rinaldi; Yurong Feng; Daniel Aronson; Marcio Malogolowkin; Kenichi Yoshimura; Ivo Leuschner; Dolores Lopez-Terrada; Tomoro Hishiki; Giorgio Perilongo; Dietrich von Schweinitz; Irene Schmid; Kenichiro Watanabe; Marisa Derosa; Rebecka Meyers
Journal:  Eur J Cancer       Date:  2015-12-01       Impact factor: 9.162

Review 10.  The SPLIT research agenda 2013.

Authors:  Estella M Alonso; Vicky L Ng; Ravinder Anand; Christopher D Anderson; Udeme D Ekong; Emily M Fredericks; Katryn N Furuya; Nitika A Gupta; Stacee M Lerret; Shikha Sundaram; Greg Tiao
Journal:  Pediatr Transplant       Date:  2013-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.